466 related articles for article (PubMed ID: 32066936)
1. Harnessing cancer immunotherapy during the unexploited immediate perioperative period.
Matzner P; Sandbank E; Neeman E; Zmora O; Gottumukkala V; Ben-Eliyahu S
Nat Rev Clin Oncol; 2020 May; 17(5):313-326. PubMed ID: 32066936
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy during the Immediate Perioperative Period: A Promising Approach against Metastatic Disease.
Sandbank E; Eckerling A; Margalit A; Sorski L; Ben-Eliyahu S
Curr Oncol; 2023 Aug; 30(8):7450-7477. PubMed ID: 37623021
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of cancer: targeting cancer during active disease or during dormancy?
Shah SA; Zarei M; Manjili SH; Guruli G; Wang XY; Manjili MH
Immunotherapy; 2017 Sep; 9(11):943-949. PubMed ID: 29338608
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
Yu WD; Sun G; Li J; Xu J; Wang X
Cancer Lett; 2019 Jun; 452():66-70. PubMed ID: 30902563
[TBL] [Abstract][Full Text] [Related]
5. Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy.
Park SY; Kim IS
Cancer Lett; 2019 Jun; 452():51-58. PubMed ID: 30910590
[TBL] [Abstract][Full Text] [Related]
6. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity.
Bakos O; Lawson C; Rouleau S; Tai LH
J Immunother Cancer; 2018 Sep; 6(1):86. PubMed ID: 30176921
[TBL] [Abstract][Full Text] [Related]
7. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches.
Goradel NH; Mohajel N; Malekshahi ZV; Jahangiri S; Najafi M; Farhood B; Mortezaee K; Negahdari B; Arashkia A
J Cell Physiol; 2019 Jun; 234(6):8636-8646. PubMed ID: 30515798
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
[TBL] [Abstract][Full Text] [Related]
11. Cancer Immunotherapies: What the Perioperative Physician Needs to Know.
Ackerman RS; Muncey AR; Aldawoodi NN; Kotha R; Getting REG
Curr Oncol Rep; 2022 Apr; 24(4):399-414. PubMed ID: 35141856
[TBL] [Abstract][Full Text] [Related]
12. Exploiting the critical perioperative period to improve long-term cancer outcomes.
Horowitz M; Neeman E; Sharon E; Ben-Eliyahu S
Nat Rev Clin Oncol; 2015 Apr; 12(4):213-26. PubMed ID: 25601442
[TBL] [Abstract][Full Text] [Related]
13. [Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer].
Schmid SC; Koll FJ; Beckert F; Seitz AK
Urologe A; 2020 Jul; 59(7):790-796. PubMed ID: 32472221
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis.
Zou P; Tang R; Luo M
Int Immunopharmacol; 2020 Jan; 78():106050. PubMed ID: 31812724
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
16. Perioperative systemic therapy for bladder cancer.
Eulitt PJ; Bjurlin MA; Milowsky MI
Curr Opin Urol; 2019 May; 29(3):220-226. PubMed ID: 30855376
[TBL] [Abstract][Full Text] [Related]
17. Side effects of immunotherapy: a constant challenge for oncologists.
Scotté F; Ratta R; Beuzeboc P
Curr Opin Oncol; 2019 Jul; 31(4):280-285. PubMed ID: 30925538
[TBL] [Abstract][Full Text] [Related]
18. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
Labbate C; Hatogai K; Werntz R; Stadler WM; Steinberg GD; Eggener S; Sweis RF
J Immunother Cancer; 2019 Mar; 7(1):66. PubMed ID: 30857555
[TBL] [Abstract][Full Text] [Related]
19. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
20. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
